These findings suggest that the inhibitory effect of probucol and cilostazol in combination through an inflammatory mediator, MCP-1 expression, in the ischemic brain with hypercholesterolemia allowed the identification of one of the mechanisms responsible for its anti-inflammatory action. This evidence concerns the gene CCL2 and Hypercholesterolemia.